| |
| |
|
| Insider
Information: |
Heron Patrick J |
| Relationship: |
Director, 10% Owner |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
18 |
|
| Direct
Shares |
33,463,806 |
|
|
Indirect Shares
|
27,246,926 |
|
|
| Direct
Value |
$751,515,997 |
|
|
|
Indirect Value
|
$164,411,499 |
|
|
| Total
Shares |
60,710,732 |
|
|
| Total
Value |
$915,927,496 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
7
|
1
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
6
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
 15.7%
|
 -59.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Trubion Pharmaceuticals, Inc |
TRBN |
10% Owner Indirect, Di... |
|
0 |
2010-10-28 |
0 |
Premium* |
|
|
Cidara Therapeutics, Inc. |
CDTX |
Director |
2015-04-20 |
0 |
2015-04-20 |
291,023 |
Premium* |
|
|
Tobira Therapeutics Inc |
TBRA |
Director |
2015-05-04 |
0 |
2015-05-04 |
2,668,570 |
Premium* |
|
|
Collegium Pharmaceutical, Inc |
COLL |
Director, 10% Owner |
2015-05-12 |
0 |
2015-05-12 |
1,887,332 |
Premium* |
|
|
Anaptysbio Inc |
ANAB |
10% Owner |
2018-05-11 |
973,612 |
2018-05-11 |
973,612 |
Premium* |
|
|
Sierra Oncology Inc |
SRRA |
10% Owner |
2017-02-14 |
8,112,121 |
|
0 |
Premium* |
|
|
Alpine Immune Sciences Inc |
ALPN |
10% Owner |
2019-01-18 |
2,571,450 |
|
0 |
Premium* |
|
|
Aptinyx Inc. |
APTX |
10% Owner |
2018-06-25 |
3,190,079 |
2018-06-25 |
0 |
Premium* |
|
|
Iterum Therapeutics Plc |
ITRM |
Director |
2020-07-01 |
9,006 |
2020-07-01 |
1,538,316 |
Premium* |
|
|
Mirum Pharmaceuticals, Inc. |
MIRM |
Director |
2019-07-22 |
0 |
2023-11-09 |
3,728,875 |
Premium* |
|
|
Phathom Pharmaceuticals, Inc. |
PHAT |
10% Owner |
2020-06-12 |
5,827,415 |
2020-06-12 |
31,446 |
Premium* |
|
|
Entasis Therapeutics Holdings Inc. |
ETTX |
10% Owner |
2020-01-09 |
1,299,953 |
2020-01-09 |
0 |
Premium* |
|
|
Arcutis Biotherapeutics, Inc. |
ARQT |
Director, 10% Owner |
2024-06-14 |
18,826 |
2024-03-04 |
8,808,979 |
Premium* |
|
|
Passage Bio, Inc. |
PASG |
Director, 10% Owner |
2020-03-03 |
0 |
2020-03-03 |
5,009,219 |
Premium* |
|
|
Vaxcyte, Inc. |
PCVX |
Director |
2020-06-16 |
0 |
2020-06-16 |
2,309,554 |
Premium* |
|
|
Tarsus Pharmaceuticals, Inc. |
TARS |
10% Owner |
2020-10-20 |
1,917,157 |
2020-10-20 |
0 |
Premium* |
|
|
Frazier Lifesciences Acquisition... |
FLAC |
Director |
2020-12-11 |
1,000,000 |
2020-12-11 |
0 |
Premium* |
|
|
Hillevax, Inc. |
HLVX |
Director, 10% Owner |
2024-04-04 |
8,544,187 |
2022-05-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
57 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ANAB |
Anaptysbio Inc |
10% Owner |
– – • |
2017-01-31 |
4 |
B |
$15.00 |
$6,000,000 |
I/I |
400,000 |
88,709 |
1.5 |
- |
|
| MIRM |
Mirum Pharmaceuticals, In... |
Director |
– • • |
2019-07-22 |
4 |
B |
$15.00 |
$6,750,000 |
I/I |
450,000 |
3,566,912 |
2.25 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Director |
– • • |
2020-02-04 |
4 |
B |
$17.00 |
$8,500,000 |
I/I |
500,000 |
10,542,790 |
2.25 |
% |
|
| PASG |
Passage Bio, Inc. |
Director |
– • • |
2020-03-03 |
4 |
B |
$18.00 |
$9,900,000 |
I/I |
550,000 |
5,009,219 |
2.25 |
% |
|
| FLAC |
Frazier Lifesciences Acqu... |
Director |
– • – |
2020-12-11 |
4 |
B |
$10.00 |
$10,000,000 |
D/D |
1,000,000 |
1,000,000 |
2.39 |
- |
|
| HLVX |
Hillevax, Inc. |
Director |
– • • |
2022-05-03 |
4 |
B |
$17.00 |
$30,000,002 |
D/D |
1,764,706 |
8,535,337 |
3.92 |
% |
|
| HLVX |
Hillevax, Inc. |
Director |
– • • |
2022-05-03 |
4 |
OE |
$13.60 |
$37,212,782 |
D/D |
2,736,234 |
6,770,631 |
0 |
- |
|
57 Records found
|
|
Page 3 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
